Verona Pharma PLC American Depositary Share’s (NASDAQ:VRNA) lock-up period will end on Tuesday, October 24th. Verona Pharma PLC American Depositary Share had issued 5,768,000 shares in its initial public offering on April 27th. The total size of the offering was $77,868,000 based on an initial share price of $13.50. After the end of Verona Pharma PLC American Depositary Share’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

A number of analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Verona Pharma PLC American Depositary Share from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Tuesday, July 25th. Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Verona Pharma PLC American Depositary Share in a report on Friday, September 8th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $24.20.

ILLEGAL ACTIVITY WARNING: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/17/verona-pharma-plc-american-depositary-shares-lock-up-period-to-end-on-october-24th-nasdaqvrna.html.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) opened at 14.66 on Tuesday. The stock’s market cap is $162.20 million. The company has a 50-day moving average of $14.92 and a 200-day moving average of $13.35. Verona Pharma PLC American Depositary Share has a 12 month low of $11.03 and a 12 month high of $17.50.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.09). On average, equities analysts forecast that Verona Pharma PLC American Depositary Share will post ($2.23) EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the business. FIL Ltd bought a new position in Verona Pharma PLC American Depositary Share during the second quarter valued at $873,000. Tekla Capital Management LLC bought a new position in Verona Pharma PLC American Depositary Share during the second quarter valued at $3,211,000. Finally, Vivo Capital LLC bought a new position in Verona Pharma PLC American Depositary Share during the second quarter valued at $8,208,000. Institutional investors and hedge funds own 30.16% of the company’s stock.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.